Sign in

CIK 0001557746

  • Non-accelerated filer
  • Smaller reporting company

Aclaris Therapeutics, Inc.

Sign in to watch
Ticker
ACRS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
460571712
Phone
+1 484-324-7933
Business address
701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Open-market buy 10% owner bought 244,200 shares at $14.00 ($3,418,800)
  6. 4 Open-market buy 10% owner bought 5,410 shares at $14.03 ($75,883)
  7. 4 Open-market buy 10% owner bought 34,999 shares at an average $14.89 ($521,095)
  8. 4 Open-market buy 10% owner bought 42,813 shares at $14.06 ($601,792)
  9. 4 Open-market buy 10% owner bought 335,455 shares at $11.00 ($3,690,005)
  10. 4 Open-market buy Director bought 454,545 shares at $11.00 ($4,999,995)
  11. 4 Open-market buy 10% owner bought 454,545 shares at $11.00 ($4,999,995)
  12. 4 Open-market buy Director bought 409,090 shares at $11.00 ($4,499,990)
  13. 4 Open-market buy 10% owner bought 409,090 shares at $11.00 ($4,499,990)
  14. 4 Conversion Chief Legal Officer acquired 3,738 shares (conversion)
  15. 4 Conversion Chief Financial Officer acquired 7,478 shares (conversion)
  16. 4 Conversion Director acquired 46,188 shares (conversion)
  17. 4 Open-market buy 10% owner bought 2,237,130 shares at an average $10.86 ($24,289,920)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Open-market buy 10% owner bought 13,352 shares at $11.00 ($146,872)
  20. 4 Open-market buy Director bought 13,352 shares at $11.00 ($146,872)

Page 20 of 21 · 414 filings